Contact induced dry eye

Article

Understanding the problems of contact lens induced dry eye

Within the general population, moderate dryeye problems can be triggered by many factors including: nutrition, ageing, medications and environmental conditions. While as low as 10% of noncontact lens wearers under the age of 60 are reported to suffer from dry eye; dryness is one of the most common problems reported by contact lens wearers and in extreme cases can lead to contact lens drop out.1

To better understand the problems of contact lens induced dry eye (CLIDE) in Sweden, we sent out a survey to 25 leading Swedish contact lens fitters with the following questions:2

Q: What percentage of your contact lens wearing patients suffer from dry eye symptoms?

Q: What is your favourite prescription for solving dry-eye symptoms?

Q: If you ask your CLIDE patients to use artificial tears, do you prefer preserved or nonpreserved products?

The results from the Swedish survey were calculated and compared to results from a similar study completed in Germany.3

Ninety-two percent (n=23) of the contact lens specialists felt that high water (>50% water) soft contact lenses were the main contributor to CLIDE. In the similar German study over 40% of respondents felt the same.

Regarding which type of artificial tear is preferred, 96% (n=24) preferred to prescribe a nonpreserved product. The German study showed very similar results.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.